**JPED-D-21-00418 - Supplementary material**

**Supplementary Figure 1 - Frequency of rhinovirus and SARS-CoV-2 detection. Lighter shading indicates that only the single pathogen was detected, and darker shading indicates the pathogen was detected in combination with at least one other pathogen. (A) 93.1% of rhinovirus single detection, and 6.9% of co-detection of adenovirus, coronavirus NL63, enterovirus or *Mycoplasma pneumoniae*, and (B) 99.0% of SARS-CoV-2 single detection, and 1.0% of co-detection of enterovirus.**

****

**Supplementary Table 1 - Probe access code for the target pathogens used in the real time PCR respiratory panel. (RVSA) Respiratory syncytial virus type A. (RVSB) Respiratory syncytial virus type B.**

|  |  |  |
| --- | --- | --- |
| **Organisms** | **Target** | **Assay ID** |
| Bacteria | *Bordetella pertussis* | Ba06439623\_s1 |
| *Chlamydophila pneumoniae* | Ba06439616\_s1 |
| *Mycoplasma pneumoniae* | Ba06439620\_s1 |
| Viruses | Adenovirus 1 and 2 | Vi99990001\_po |
| Bocavirus | Vi99990003\_po |
| Coronavirus HKU1 | Vi06439674\_s1 |
| Coronavirus 229E | Vi06439671\_s1 |
| Coronavirus NL63 | Vi06439673\_s1 |
| Coronavirus OC43 | Vi06439646\_s1 |
| Influenza A H1 | Vi99990009\_po |
| Influenza A H3 | Vi06439630\_s1 |
| Influenza B PAN | Vi06439668\_s1 |
| Human Enterovirus | Vi06439631\_s1 |
| Metapneumovirus | Vi99990004\_po |
| Parainfluenza 1 | Vi06439642\_s1 |
| Parainfluenza 2 | Vi06439672\_s1 |
| Parainfluenza 3 | Vi06439670\_s1 |
| RSVA | Vi99990014 |
| RSVB | Vi99990015 |
| Rhinovirus | Vi99990016\_po |

**Supplementary Table 2 - Clinical and demographic characteristics, and pathogen detection of the included subjects. (IQR) Interquartile range. (FLU) Influenza. (ICU) Intensive care units.**

|  |  |  |
| --- | --- | --- |
| **Characteristics** | **Total****(n = 436)** | **Losses****(n = 14)** |
| Age, median (IQR) | 5.4 (2.0-10.2) | 7.3 (1.6-10.3) |
| Female sex, n (%) | 233 (53.4) | 9 (64.3) |
| **Racial or ethnic group** |  |  |
| Caucasian, n (%) | 301/417 (72.2) | - |
| Non-caucasian, n (%) | 116/417 (27.8) | - |
| **Duration of symptoms at inclusion** |  |  |
| Days, median (IQR) | 3.0 (1.0-4.0) | 2.0 (2.0-2.0) |
| **Duration of symptoms at hospitalization** |  |  |
| Days, median (IQR) | 2.0 (1.0-5.2) | - |
| **Hospital at inclusion** |  |  |
| Private hospital, n (%) | 215 (49.3) | 4 (28.6) |
| Public hospital, n (%) | 221 (50.7) | 10 (71.4) |
| **Pathogens** |  |  |
| Adenovirus | 6/434 (1.4) | 0 (0.0) |
| *Chlamydophila pneumoniae* | 1/434 (0.2) | 0 (0.0) |
| Coronavirus NL63 | 2/434 (0.5) | 0 (0.0) |
| Enterovirus | 7/434 (1.6) | 0 (0.0) |
| Human metapneumovirus | 2/434 (0.5) | 0 (0.0) |
| *Mycoplasma pneumoniae* | 6/434 (1.4) | 0 (0.0) |
| Rhinovirus | 216/434 (49.8) | 10 (71.4) |
| SARS-CoV-2 | 97 (22.2) | 5 (35.7) |
| **Coinfections** |  |  |
| Rhinovirus and SARS-CoV-2 | 31 (7.1) | 2 (14.3) |
| SARS-CoV-2 and enterovirus | 1 (0.2) | 0 (0.0) |
| Rhinovirus and others | 15 (3.4) | 0 (0.0) |
| None pathogens | 145 (33.3) | 13 (92.9) |
| **Use of azithromycin at inclusion** |  |  |
| Yes, n (%) | 14 (3.2) | 0 (0.0) |
| **Use of other antibiotics at inclusion** |  |  |
| Yes, n (%) | 13 (3.0) | 0 (0.0) |
| **FLU vaccination** |  |  |
| Yes, n (%) | 262 (60.1) | - |
| **Underlying medical conditions** |  |  |
| Asthma, n (%) | 68 (15.6) | 4 (28.6) |
| Diabetes mellitus, type 1, n (%) | 1 (0.2) | 0 (0.0) |
| Obesity, n (%) | 1/233 (0.4) | 0 (0.0) |
| Hypertension, n (%) | 1 (0.2) | 0 (0.0) |
| **Symptoms at inclusion** |  |  |
| Cough, n (%) | 313/435 (72.0) | 10 (71.4) |
| Coryza, n (%) | 302 (69.3) | 10 (71.4) |
| Sore throat, n (%) | 163/388 (42.0) | 8/12 (66.7) |
| Stuffy nose, n (%) | 218/432 (50.5) | 8 (57.1) |
| Dyspnea, n (%) | 148/429 (34.5) | 3 (21.4) |
| Sputum production, n (%) | 154 (35.3) | 4 (28.6) |
| Nausea, n (%) | 121/419 (28.9) | 8 (57.1) |
| Diarrhea, n (%) | 112/434 (25.8) | 2 (14.3) |
| Vomiting, n (%) | 99/436 (22.7) | 4 (28.6) |
| Fever, n (%) | 302/435 (69.4) | 11 (78.6) |
| Headache, n (%) | 195/373 (52.3) | 7/10 (70.0) |
| Malaise, n (%) | 201/425 (47.3) | 8 (57.1) |
| Myalgia, n (%) | 97/386 (22.2) | 4/11 (36.4) |
| Chills, n (%) | 118/413 (28.6) | 5/12 (41.7) |
| Dysgeusia, n (%) | 40/322 (12.4) | 2/9 (22.2) |
| Anosmia, n (%) | 39/324 (12.0) | 3/9 (33.3) |
| Appetite loss, n (%) | 212/432 (49.1) | 10 (71.4) |
| Conjunctivitis, n (%) | 82/432 (19.0) | 3/13 (23.1) |
| Skin rash, n (%) | 32/433 (7.4) | 1 (7.1) |
| **Hospitalization** |  |  |
| Use of supplemental oxygen, n (%) | 21 (4.8) | - |
| Admission at ICU, n (%) | 4 (0.9) | - |
| Use of invasive mechanical ventilation, n (%) | 0 (0.0) | - |
| Deaths, n (%) | 0 (0.0) | - |

**Supplementary Table 3 - Absolute number of tested pathogens and the frequency of detected ones.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Pathogen** | **Tested** | **Detected** | **Percent** |
| Adenovirus | 434 | 6 | 1.4 |
| Bocavirus | 434 | 0 | 0.0 |
| *Bordetella pertussis* | 434 | 0 | 0.0 |
| *Chlamydophila pneumoniae* | 434 | 1 | 0.2 |
| **Other Coronaviridae** |  |  |  |
|  Coronavirus HKU1 | 433 | 0 | 0.0 |
|  Coronavirus OC43 | 434 | 0 | 0.0 |
|  Coronavirus NL63 | 434 | 2 | 0.5 |
|  Coronavirus 229E | 434 | 0 | 0.0 |
| Enterovirus | 434 | 7 | 1.6 |
| **Influenza** |  |  |  |
|  Influenza A (H1) | 434 | 0 | 0.0 |
|  Influenza A (H3) | 434 | 0 | 0.0 |
|  Influenza B | 434 | 0 | 0.0 |
| Human metapneumovirus | 434 | 2 | 0.5 |
| *Mycoplasma pneumoniae* | 434 | 6 | 1.4 |
| **Parainfluenza virus** |  |  |  |
|  Parainfluenza 1 | 434 | 0 | 0.0 |
|  Parainfluenza 2 | 434 | 0 | 0.0 |
|  Parainfluenza 3 | 434 | 0 | 0.0 |
| Rhinovirus | 434 | 216 | 49.8 |
| **Respiratory syncytial virus** |  |  |  |
|  Respiratory syncytial virus A | 434 | 0 | 0.0 |
|  Respiratory syncytial virus B | 434 | 0 | 0.0 |